1. Accueil
  2. FR
  3. La Recherche
  4. Innovation et entreprises

The CMMI welcomes a next-generation platform for in vivo isotopic imaging

Publié le 12 mai 2026 – Mis à jour le 13 mai 2026

The CMMI, a ULB-UMONS technology platform based in the BioPark Charleroi, has installed a new cutting-edge imaging system within the nuMIx unit, marking a major step forward in its preclinical molecular imaging capabilities. Acquired with the support of the ERDF and the Walloon Region, this investment reinforces the CMMI's mission to deliver advanced imaging solutions for high-impact preclinical research.

CMMI equipment


The new instrument is a multimodal camera that generates in vivo TEMP/PET/CT/ARG preclinical images, bringing all major imaging modalities together on a single, highly versatile platform. By combining these complementary techniques, the system supports a wide range of isotopes and offers unprecedented flexibility for preclinical studies.

The platform will open up applications across multiple research fields:

  • Oncology – tumour metabolism and microenvironment, treatment follow-up, bench-to-bedside studies in radiotheranostics
  • Neurology – Alzheimer's disease studies
  • Immunology – lung inflammation, rheumatoid polyarthritis
  • Fibrosis – idiopathic pulmonary fibrosis

It can also produce data required by drug agencies for marketing authorisation, particularly in cell therapy. The new platform will seamlessly integrate with the CMMI's existing imaging technologies, creating a comprehensive and coherent imaging environment.

A key strength is the ability to image both positron-emitting and photon-emitting isotopes within the same system, a decisive advantage for radiotheranostics, the rapidly growing approach combining diagnostic and therapeutic agents in oncology. Until now, the high-energy isotopes increasingly used in modern theranostics could not be imaged at the CMMI. The new equipment removes this barrier, enabling high-quality combined imaging and improving the accuracy, robustness, and translational relevance of these studies.

A first concrete milestone: on 11 March 2026, the Accelerate.eu EU-HORIZON-JU-IHI consortium delivered Astatine-211 in Belgium for the very first time. Thanks to the new platform, the CMMI was directly involved in this event, generating images of the product vial that were then used to calibrate the equipment's quantification of this radioisotope.

The CMMI is fully open to collaborating with academic and industrial partners on innovative projects, offering imaging expertise, tailored scientific support, and access to a state-of-the-art infrastructure.

For project discussions, feasibility assessments, or collaboration opportunities, please contact the CMMI at info@cmmi.be

More info on the CMMI website

©Source: CMMI/BioPark Charleroi